US Stock MarketDetailed Quotes
LRTX Lirum Therapeutics
- 0.000
- 0.0000.00%
Close Jun 18 09:30 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)9.27MShares0.00052wk High0.00P/B0Float Cap0.00052wk Low--Dividend TTM4.58MShs Float0.000Historical High--Div YieldTTM0.00%Amplitude0.000Historical Low--Avg Price1Lot Size
About Lirum Therapeutics Company
Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY.
Company Profile
SymbolLRTX
Company NameLirum Therapeutics
Founded2021
CEOMr. Peter McDonald
MarketNASDAQ
Employees3
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address590 Madison Avenue,21st floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10022
Phone1-646-964-1402
Websitehttp://www.lirumtx.com
Company Executives
- Name
- Position
- Salary
- Peter McDonald
- Chief Executive Officer, Interim Principal Financial and Accounting Officer
- --
- Kenneth Hoberman
- Vice Chairman of the Board
- --
- Dr. Ivan Bergstein
- Chairman of the Board
- --
- Mark Sard
- Independent Director
- --
- Kenneth J. Zuerblis
- Independent Director
- --
- Daniel Hume
- Independent Director
- --
- Alan S. Forman
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg